Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | LGMN | Q99538 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625302 | 0.88 | HDAC3 (0.42) | TLR7PDE2ACTNNB1WNT3A | |
| SCHEMBL627876 | 0.85 | TLR7 (0.48) | TLR7PDE2ASLC6A4SLC6A3EPHX2 | |
| SCHEMBL628363 | 0.83 | HSD11B1 (0.52) | SLC6A3MEN1KMT2ACTNNB1WNT3A | |
| SCHEMBL628166 | 0.83 | KDM4E (0.47) | MEN1KMT2ACTNNB1WNT3A | |
| SCHEMBL627096 | 0.81 | TLR7 (0.45) | TLR7SLC6A4SLC6A3EPHX2 | |
| SCHEMBL623939 | 0.80 | TLR7 (0.53) | TLR7PDE2ANR1I2MEN1KMT2A | |
| SCHEMBL15011057 | 0.78 | HSD11B1 (0.57) | PDE2ASLC6A4SLC6A3EPHX2S1PR1 | |
| SCHEMBL625891 | 0.77 | SLC6A4 (0.49) | TLR7SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL626251 | 0.75 | SLC6A4 (0.43) | TLR7SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL625409 | 0.75 | TRPV3 (0.49) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TLR7 1619/4885PDE2A 807/4885SLC6A4 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.